GSK sees positive results in Gemini 1 and 2 trials in untreated

GEMINI 1 and 2 trials in untreated HIV confirm that GSK’s combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) has matched the efficacy of dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in previously-untreated patients, regardless of the viral load of patients, and treatment failure was less than 1% with no treatment resistance identified in both. Regulatory approval for this new combination will be sought later this year.

GEMINI lead investigator Pedro Cahn, said: “These are important findings for people living with HIV who will spend their lifetime taking drugs to suppress their virus. Now that we have more potent drugs, the focus is shifting to tolerability and convenience.”